Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | NPY1R | P25929 | 1/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29223458 | 0.88 | LMNA (0.56) | MAP2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL8689806 | 0.88 | MAP2 (0.62) | MAP2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL15711419 | 0.87 | MAP2 (0.64) | MAP2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1144990 | 0.86 | GPR17 (0.60) | MEN1KMT2ALMNAHPGD | |
| SCHEMBL6921821 | 0.84 | MAP2 (0.65) | MAP2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL6848947 | 0.83 | MAPT (0.64) | MAP2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL27372699 | 0.83 | MAP2 (0.63) | MAP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL27444071 | 0.83 | MAP2 (0.63) | MAP2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL2816058 | 0.82 | ALDH1A1 (0.67) | MEN1KMT2AALDH1A1POLBPKM | |
| SCHEMBL4077176 | 0.82 | ALDH1A1 (0.69) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | claimed |
| EP-4660193-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024162746-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | 한국화학연구원 | 2024-08-08 | — | — | WO | disclosed |
| US-20220257569-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2022-08-18 | — | — | US | disclosed |
| WO-2020051707-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2020-03-19 | — | — | WO | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| WO-2012117216-A1 | N- (ARYLALKYL) - 1H- INDOLE- 2 - SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-09-07 | — | — | WO | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| CN-101790313-A | Compound (I) | SMITHKLINE BEECHAM CORP | 2010-07-28 | — | — | CN | disclosed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | disclosed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | disclosed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6288103-B1 | MONOCYTE CHEMOATTRACTANT PROTEINS ANTAGONIST SUCH AS N-(3-CHLOROPHENYLSULPHONYL)INDOLE-2-CARBOXYLIC ACID; ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2001-09-11 | — | — | US | disclosed |
| EP-1001935-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999007678-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1140709-A | Substituted N- (indole-2-carbonyl) -beta-alaninamides and derivatives as antidiabetics | PFIZER (US) | 1997-01-22 | — | — | CN | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | MAP2 722/4885MEN1 2427/4885KMT2A 2064/4885 |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | MAP2 722/4885MEN1 2427/4885KMT2A 2064/4885 |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | MAP2 3698/4885MEN1 3262/4885KMT2A 2221/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | MAP2 2083/4885MEN1 3585/4885KMT2A 751/4885 |
| US-20220257569-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | CNR2, GPR119, CNR1 | MAP2 1000/4885MEN1 4146/4885KMT2A 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.